Cat. No.: HY-151799

P62-RNF168 agonist-1

Customer Review

Based on 1 Customer Validation

P62-RNF168 agonist-1 (compound 5a) is a low cytotoxicity P62-RNF168 agonist that enhances the interaction between P62 and RNF168. P62-RNF168 agonist-1 induces a reduction in H2A ubiquitination mediated by RNF168 and impairs homologous recombination-mediated DNA repair. P62-RNF168 agonist-1 also inhibits the growth of xenograft tumors in mice in a dose-dependent manner.

For research use only. We do not sell to patients.

Purity: 98.03%
CAS No.: 2765180-17-2
Formula: C₁₉H₁₉N₇O₃
Molecular Weight:393.40

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

P62-RNF168 agonist-1 Chemical Structure

CAS No.: 2765180-17-2

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	1.93 μM Compound: 5a	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]
A549	IC₅₀	1.18 μM Compound: 5a	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]
HCT-116	IC₅₀	0.36 μM Compound: 5a	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]
HeLa	IC₅₀	2.48 μM Compound: 5a	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]
HepG2	IC₅₀	19.61 μM Compound: 5a	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]
MCF-10A	IC₅₀	6.98 μM Compound: 5a	Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MCF-10A cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]
MCF7	IC₅₀	2.79 μM Compound: 5a	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]
MDA-MB-231	IC₅₀	1.17 μM Compound: 5a	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]
MGC-803	IC₅₀	1.88 μM Compound: 5a	Cytotoxicity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]
U2OS	IC₅₀	3.64 μM Compound: 5a	Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 36331508]

In Vitro

P62-RNF168 agonist-1 (20 μM, 72 h) has an IC₅₀ of 0.36 μM for the cancer cell line HCT116 and an IC₅₀ of 1.18 μM for A549. It shows cytotoxicity against cancer cells A357, HeLa, HepG2, MCF-7, MDA-MB-231, MGC-803, and H2OS, but does not induce cell apoptosis and has lower toxicity towards normal cells MCF-10A^[1].
P62-RNF168 agonist-1 (1-5 μM; 24 h) affects the HR (homologous recombination)-mediated DSB repair in HCT-116 cells, contributing to its antitumor activity^[1].
P62-RNF168 agonist-1 enhances the interaction between P62 and RNF168 in HCT-116 cells, with a K_d of 20.97 μM^[1].
P62-RNF168 agonist-1 inhibits the catalytic activity of RNF168 and the E3 ligase activity of RNF168 in HCT-116 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

A549, HCT-116, A375, HeLa, HepG2, MCF-7, MDA-MB-231, MGC-803, U2OS and MCF-10A cells
Concentration:

0-20 µM
Incubation Time:

72 h
Result:

Inhibited A549, HCT-116, A375, HeLa, HepG2, MCF-7, MDA-MB-231, MGC-803, U2OS and MCF-10A cells, with IC₅₀ values of 1.18, 0.36, 1.93, 2.48, 19.61, 2.79, 1.17, 1.88, 3.64 and 6.98, respectively.

Cell Cycle Analysis^[1]

Cell Line:

HCT-116 cells
Concentration:

1, 2, 5 µM
Incubation Time:

24 h
Result:

Induced a G2/M arrest but no significant accumulation of sub-G1 phase.
Compromised both HR(homologous recombination)- and NHEJ (non-homologous end joining)- mediated DSB repair in a dose-dependent manner, but HR was the more severely impacted process.

Western Blot Analysis^[1]

Cell Line:

HCT-116
Concentration:

10 µM
Incubation Time:

Over night
Result:

Had the expression of RNF168 and GST-RNF168 ,increased the level of P62 in the endogenous RNF-168 immune complex.

Apoptosis Analysis^[1]

Cell Line:

HCT-116
Concentration:

5, 10 µM
Incubation Time:

24 h
Result:

Made apoptosis less obvious.

In Vivo

P62-RNF168 agonist-1 (12.5-100 mg/kg, i.p., single dose) has an MTD of 50 mg/kg in BALB/c mice, while in female nude mice, the MTD is 12.5 mg/kg^[1].
P62-RNF168 agonist-1 (5-10 mg/kg, i.p., single every 3 days for 22 days) promotes tumor apoptosis and inhibits tumor growth in mice^[1].
1.19 Pharmacokinetic Parameters of Antitumor agent-81 in Female BALB/c nude mice^[1].

Dose	T_1/2 (h)	C_max (ng/mL)	AUC_0-t (h?ng/mL)	CL ((mL/h)/kg)
IP (5 mg/kg)	16.17	26.10	215.69	19647.83
IP (10 mg/kg)	31.00	39.87	408.18	16554.30
IP (20 mg/kg)	22.10	52.23	1003.58	14669.81

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female BALB/c nude mice (xenograft tumor model)^[1].
Dosage:

5, 10 mg/kg
Administration:

Intraperitoneal injection; single every 3 days for 22 days
Result:

Suppressed tumor growth by promoting apoptosis in xenografted tumorigenesis.

Animal Model:

Female BALB/c nude mice^[1].
Dosage:

5, 10, 20 mg/kg
Administration:

Intraperitoneal injection; single
Result:

Exhibited plasma concentration peaked 1 h after administration.
Showed a relatively high maximum concentration (C_max= 52.23 ng/mL) and exposure (AUC_0-t= 1003.58 h•ng/mL) at a dose of 20 mg/kg.

Animal Model:

BALB/c mice, Female nude mice^[1]
Dosage:

25, 50, 75, 100 mg/kg, single dose; 12.5, 25, 50 mg/kg, single dose
Administration:

Intraperitoneal injection
Result:

Showed in the 100 mg/kg dosage group of BALB/c mice, out of 8 animals, 3 males and 3 females died on the 7th day, and the remaining animals experienced diarrhea. In the 75 mg/kg dosage group, 1 out of 8 animals (1 male) had diarrhea on the 7th day. There were no deaths or diarrhea observed in the ≤50 mg/kg dosage group.
Showed in the female nude mice, both the 25 and 50 mg/kg dosage groups experienced deaths or diarrhea, while the 12.5 mg/kg dosage group had no deaths or diarrhea.

Chemical Information

CAS No. 2765180-17-2
Appearance Solid
Molecular Weight 393.40
Formula C₁₉H₁₉N₇O₃
Color Off-white to light yellow
SMILES

NC1=C2C(C=CC(C3=CN(C4=CC(OC)=C(C(OC)=C4)OC)N=N3)=C2)=NC(N)=N1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 60 mg/mL (152.52 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5419 mL

12.7097 mL

25.4194 mL

5 mM

0.5084 mL

2.5419 mL

5.0839 mL

10 mM

0.2542 mL

1.2710 mL

2.5419 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.4 mg/mL (6.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.4 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (24.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.4 mg/mL (6.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.4 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (24.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.4 mg/mL (6.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.4 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (24.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Wang FC, et al. A 1,2,3-Triazole Derivative of Quinazoline Exhibits Antitumor Activity by Tethering RNF168 to SQSTM1/P62. J Med Chem. 2022 Nov 4. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5419 mL	12.7097 mL	25.4194 mL	63.5486 mL
	5 mM	0.5084 mL	2.5419 mL	5.0839 mL	12.7097 mL
	10 mM	0.2542 mL	1.2710 mL	2.5419 mL	6.3549 mL
	15 mM	0.1695 mL	0.8473 mL	1.6946 mL	4.2366 mL
	20 mM	0.1271 mL	0.6355 mL	1.2710 mL	3.1774 mL
	25 mM	0.1017 mL	0.5084 mL	1.0168 mL	2.5419 mL
	30 mM	0.0847 mL	0.4237 mL	0.8473 mL	2.1183 mL
	40 mM	0.0635 mL	0.3177 mL	0.6355 mL	1.5887 mL
	50 mM	0.0508 mL	0.2542 mL	0.5084 mL	1.2710 mL
	60 mM	0.0424 mL	0.2118 mL	0.4237 mL	1.0591 mL
	80 mM	0.0318 mL	0.1589 mL	0.3177 mL	0.7944 mL
	100 mM	0.0254 mL	0.1271 mL	0.2542 mL	0.6355 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

P62-RNF168 agonist-1

Apoptosis Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Oxygen Sensing Compound Library

Ubiquitination Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

P62-RNF168 agonist-1

Apoptosis Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Oxygen Sensing Compound Library

Ubiquitination Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Amino Acid Metabolism Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

P62-RNF168 agonist-1 Related Classifications

Cat. No.: HY-151799